Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
Revenue (Most Recent Fiscal Year) | $48.73M |
Net Income (Most Recent Fiscal Year) | $-61.32M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 1.55 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.40 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -34.74% |
Net Margin (Trailing 12 Months) | -48.10% |
Return on Equity (Trailing 12 Months) | -131.69% |
Return on Assets (Trailing 12 Months) | -22.73% |
Current Ratio (Most Recent Fiscal Quarter) | 4.82 |
Quick Ratio (Most Recent Fiscal Quarter) | 4.82 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $5.37 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.35 |
Earnings per Share (Most Recent Fiscal Year) | $-11.07 |
Diluted Earnings per Share (Trailing 12 Months) | $-7.47 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 6.93M |
Free Float | 6.65M |
Market Capitalization | $89.34M |
Average Volume (Last 20 Days) | 0.04M |
Beta (Past 60 Months) | 1.62 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.00% |
Percentage Held By Institutions (Latest 13F Reports) | 37.99% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |